International Journal of Hematology

, Volume 87, Issue 2, pp 167–171

Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis

  • Ying Wang
  • Depei Wu
  • Aining Sun
  • Zhengming Jin
  • Huiying Qiu
  • Miao Miao
  • Xiaowen Tang
  • Zhengzheng Fu
Original Article

Abstract

The prognosis for patients with chronic myeloid leukemia (CML) in blast crisis (BC) remains dismal even with the availability of the BCR-ABL tyrosine kinase inhibitor imatinib, since it only offers short-term benefit in most cases. Allogeneic hematopoietic stem cell transplantation (HSCT) seems to be a viable option for BC-CML patients who attained remission. We treated ten patients with ablative allogeneic HSCT, who achieved second chronic phase (CP) by the use of imatinib after onset of BC. Median patient age was 32 years (range 17–46). Among them, four patients received HSCT from human leukocyte antigen mismatched haplo-identical family donors. After a median follow-up of 24 months (range 8–42), six out of the ten patients were alive in durable complete cytogenetic remission, one patient died in relapse 4 months after transplantation, the others died of severe acute graft-versus-host disease and associated infections. No unusual organ toxicities and engraftment difficulties were observed. Extensive chronic GVHD developed in three of six patients who could be evaluated. Patients transplanted with haplo-identical donors had a high treatment-related modality. Allogeneic HSCT may represent a feasible treatment for patients with CML in second CP attained by imatinib after onset of BC especially when a suitable donor is available.

Keywords

Hematopoietic stem cell transplantation Chronic myeloid leukemia Imatinib Blast crisis 

References

  1. 1.
    Sawyers CL. Chronic myeloid leukemia. New Engl J Med. 1999;340:1330–40.PubMedCrossRefGoogle Scholar
  2. 2.
    Sacchi S, Kantarjian HM, O’Brien S, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632–41.PubMedCrossRefGoogle Scholar
  3. 3.
    Derderian PM, Kantarjian HM, Talpaz M, et al. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993;94:69–74.PubMedCrossRefGoogle Scholar
  4. 4.
    Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–53.PubMedCrossRefGoogle Scholar
  6. 6.
    O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004.PubMedCrossRefGoogle Scholar
  7. 7.
    Gratwohl A, Baldomero H, Horisberger B, et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood. 2002;100:2374– 86.PubMedCrossRefGoogle Scholar
  8. 8.
    Gratwohl A, Hermans J. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 1996;17(suppl 3):S7–9.PubMedGoogle Scholar
  9. 9.
    Visani G, Rosti G, Bandini G, et al. Second chronic phase before transplantation is crucial for improving survival of blastic phase chronic myeloid leukaemia. Br J Haematol. 2000;109:722–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med. 1986;314:729–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226–35.PubMedGoogle Scholar
  12. 12.
    Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825–8.PubMedGoogle Scholar
  13. 13.
    Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.PubMedCrossRefGoogle Scholar
  14. 14.
    Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica. 2003;88:1213–20.PubMedGoogle Scholar
  15. 15.
    Fruehauf S, Topaly J, Buss EC, et al. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer. 2007;109:1543–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Zaucha JM, Prejzner W, Giebel S, et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone marrow Transplant. 2005;36:417–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006;91:452–9.PubMedGoogle Scholar
  18. 18.
    Zander A, Zabelina T, Renges H, et al. Pretreatment with Glivec increases transplant-related mortality after allogeneic transplant. Blood. 2003;102:468a.Google Scholar
  19. 19.
    Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107:3065–73.PubMedCrossRefGoogle Scholar
  20. 20.
    Weisser M, Schleuning M, Haferlach C, Schwerdtfeger R, Kolb HJ. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48:295–301.PubMedCrossRefGoogle Scholar
  21. 21.
    Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006;108:1809–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–41.PubMedCrossRefGoogle Scholar
  23. 23.
    Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007;109:3207–13.PubMedCrossRefGoogle Scholar
  24. 24.
    Jabbour E, Cortes J, Kantarjian HM, et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood. 2006;108:1421–3.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Ying Wang
    • 1
  • Depei Wu
    • 1
  • Aining Sun
    • 1
  • Zhengming Jin
    • 1
  • Huiying Qiu
    • 1
  • Miao Miao
    • 1
  • Xiaowen Tang
    • 1
  • Zhengzheng Fu
    • 1
  1. 1.Department of HematologyFirst Affiliated Hospital of Soochow University, Jiangsu Institute of HematologySuzhouChina

Personalised recommendations